Effect of Flozin (dapagliflozin) Administration on Myocardial and Peripheral Vascular Remodeling

Launched by POZNAN UNIVERSITY OF MEDICAL SCIENCES · Nov 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called dapagliflozin (also known as flozin) on patients with heart failure. Specifically, the researchers want to see how this treatment affects heart function and blood vessels in patients who have moderate to severe heart failure (classified as NYHA class II and III). Participants will take a daily dose of 10mg of dapagliflozin while continuing their current heart failure medications.

To join the study, participants must be diagnosed with heart failure and already be receiving certain heart medications, including an ACE inhibitor or similar drugs, a beta-blocker, and a mineralocorticoid receptor antagonist (MRA). The study is open to adults aged 65 and older, and both men and women can participate. Those who decide to take part in the trial can expect regular check-ups to monitor their health and the effects of the medication. This research aims to improve treatment options for people living with heart failure, and participants will play an important role in advancing our understanding of this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • diagnosed heart failure NYHA class II and III
• • consent to participate in the study
• • patients should already be receiving treatment with an ACE inhibitor or sacubitril/valsartan or sartans, a beta-blocker, and an MRA, and should start on SGLT2i as part of therapy enhancement
• Exclusion Criteria:
• • -